Sandu Pharmaceuticals quarterly results and financials

Sandu Pharmaceuticals (BSE 524703)₹36.72−0.62%(6 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Sandu Pharmaceuticals reported sales of ₹16.91 Cr, up 19.9% from Mar 2025, and net profit of ₹0.03 Cr, down 90.6% year on year. For the year to Mar 2026, sales were ₹70.17 Cr and net profit ₹1.76 Cr.

Sales (Mar 2026): ₹16.91 Cr
Net profit (Mar 2026): ₹0.03 Cr
Sales (FY Mar 2026): ₹70.17 Cr
Net profit (FY Mar 2026): ₹1.76 Cr
EPS (Mar 2026): ₹0.05
Borrowings (Mar 2026): ₹0.41 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Sandu Pharmaceuticals quarterly results

₹ crore unless stated; each column is a quarter.

Sandu Pharmaceuticals Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	17.72	16.66	17.48	15.64	17.11	17.74	18.42	14.10	16.76	17.68	18.82	16.91
Expenses	17.29	15.77	16.89	14.97	16.63	16.75	17.36	13.61	16.15	16.75	17.71	16.26
Operating Profit	0.36	0.83	0.52	0.61	0.42	0.93	1.01	0.46	0.54	0.87	1.05	0.58
OPM %	2.0%	5.0%	2.9%	3.9%	2.4%	5.2%	5.5%	3.2%	3.2%	4.9%	5.6%	3.4%
Other Income	0.00	0.10	0.04	0.32	0.05	0.04	0.03	0.08	0.03	0.06	0.02	0.38
Interest	0.01	0.00	0.01	0.00	0.01	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Depreciation	0.13	0.14	0.15	0.20	0.17	0.18	0.20	0.16	0.19	0.18	0.18	0.17
Profit before tax	0.20	0.76	0.37	0.70	0.26	0.74	0.79	0.33	0.33	0.70	0.84	0.74
Tax %	47.6%	27.2%	44.7%	16.9%	40.7%	31.9%	30.0%	2.9%	35.2%	26.7%	−14.2%	93.3%
Net Profit	0.10	0.54	0.20	0.58	0.16	0.49	0.55	0.32	0.21	0.51	0.97	0.03
EPS (Rs)	0.12	0.58	0.23	0.62	0.19	0.53	0.59	0.35	0.24	0.55	1.02	0.05

Sandu Pharmaceuticals profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Sandu Pharmaceuticals Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	38.94	42.94	49.16	49.58	48.49	58.95	65.68	65.49	67.46	67.35	70.17	70.17
Expenses	35.95	40.91	46.51	47.28	46.85	56.53	62.61	62.76	64.87	64.41	66.83	66.87
Operating Profit	2.90	1.86	2.48	2.10	1.46	2.17	2.89	2.50	2.31	2.77	3.01	3.04
OPM %	7.5%	4.3%	5.1%	4.3%	3.0%	3.7%	4.4%	3.8%	3.4%	4.1%	4.3%	4.3%
Other Income	0.13	0.57	0.13	0.58	0.46	0.20	0.09	0.34	0.43	0.18	0.45	0.49
Interest	1.63	1.48	1.22	1.00	0.42	0.10	0.10	0.07	0.05	0.09	0.10	0.08
Depreciation	0.70	0.88	0.61	0.65	0.56	0.57	0.54	0.53	0.59	0.68	0.69	0.72
Profit before tax	0.67	0.04	0.75	1.00	0.91	1.67	2.31	2.21	2.07	2.15	2.64	2.61
Tax %	22.0%	1,000.0%	26.3%	34.6%	21.7%	35.1%	31.4%	31.1%	29.3%	28.2%	33.5%	—
Exceptional items	−0.03	−0.58	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Net Profit	0.53	−0.43	0.55	0.66	0.71	1.08	1.58	1.51	1.45	1.54	1.76	1.72
EPS (Rs)	0.77	−0.63	0.80	0.96	1.03	1.39	1.81	1.58	1.52	1.61	1.84	1.86
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	36.3%	41.6%	0.0%	52.9%	49.8%	54.6%	—

Sandu Pharmaceuticals balance sheet

₹ crore, at each year end.

Sandu Pharmaceuticals Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	7.07	7.07	7.07	7.07	7.07	7.07	7.90	8.80	9.65	9.65	9.65	9.64
Reserves	11.09	11.63	20.37	21.04	21.76	22.20	25.61	27.71	29.63	30.99	32.42	34.07
Borrowings	12.48	11.40	10.57	9.41	6.18	1.24	0.03	0.00	0.00	0.00	0.00	0.41
Other Liabilities	10.87	11.34	8.42	7.00	8.64	10.91	13.44	12.78	14.91	11.79	13.71	11.77
Total Liabilities	41.51	41.44	46.43	44.52	43.65	41.42	46.98	49.29	54.19	52.43	55.78	55.89
Fixed Assets	8.35	7.80	17.47	17.54	17.02	16.59	16.16	15.98	16.61	17.86	18.14	18.12
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.41	0.00	0.00	0.05
Investments	0.71	0.74	1.00	1.13	1.14	0.83	0.25	9.13	9.69	10.45	11.26	12.35
Other Assets	32.45	32.90	27.96	25.85	25.49	24.00	30.57	23.71	27.48	24.12	26.38	25.37
Inventories	12.69	12.05	10.70	11.45	13.28	14.38	11.15	11.28	14.35	12.26	14.16	10.48
Trade receivables	6.55	7.14	6.34	6.68	4.79	4.67	5.34	3.98	4.78	4.86	4.75	5.40
Cash & equivalents	4.12	0.68	2.68	1.40	0.78	1.53	11.64	4.16	2.28	1.19	2.64	6.85
Total Assets	41.51	41.44	46.43	44.52	43.65	41.42	46.98	49.29	54.19	52.43	55.78	55.89

Sandu Pharmaceuticals cash flow

₹ crore, for each year.

Sandu Pharmaceuticals Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	4.74	−1.42	4.90	1.24	3.73	6.19	7.60	0.96	0.23	0.75	0.96	6.11
Cash from investing activity	−0.17	0.04	−0.58	−0.61	−0.09	−0.36	−5.56	−5.45	0.52	−1.30	−0.17	−0.56
Cash from financing activity	−1.89	−2.05	−2.32	−1.88	−4.25	−5.35	1.29	0.92	0.57	−0.71	−0.45	−0.93
Net cash flow	2.68	−3.43	2.00	−1.27	−0.63	0.47	3.30	−3.58	1.34	−1.26	0.30	4.61
Capex	0.31	0.14	0.60	0.67	0.10	0.10	0.12	0.83	1.06	1.42	0.93	0.71
Free cash flow	4.42	−1.59	4.31	0.61	3.64	6.10	7.47	0.10	−0.84	−0.68	0.00	5.41
CFO / OP %	201.0%	−42.0%	195.0%	63.0%	194.0%	437.0%	373.0%	64.0%	37.0%	55.0%	55.0%	229.0%

Sandu Pharmaceuticals ratios

Working-capital days and returns, by year.

Sandu Pharmaceuticals Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	63	67	54	50	35	35	33	22	27	26	26	28
Inventory days	211	208	153	148	192	210	119	116	169	138	162	122
Days payable	102	100	57	38	60	83	70	69	97	46	50	51
Cash conversion cycle	169	173	148	158	166	160	81	68	96	117	136	98
Working capital days	69	106	62	31	41	73	41	43	53	58	64	43
ROCE %	6.8%	7.8%	4.3%	5.2%	5.6%	4.2%	5.6%	7.0%	6.1%	5.4%	5.5%	6.5%

Sandu Pharmaceuticals: frequently asked questions

What are the latest quarterly results of Sandu Pharmaceuticals?

For the Mar 2026 quarter, Sandu Pharmaceuticals reported sales of ₹16.91 Cr, up 19.9% year on year and net profit of ₹0.03 Cr, down 90.6% year on year. The operating margin was 3.4%.

What is the annual revenue of Sandu Pharmaceuticals?

Sandu Pharmaceuticals' sales for the year to Mar 2026 were ₹70.17 Cr; over the last twelve months they were ₹70.17 Cr.

What is the net profit of Sandu Pharmaceuticals?

Net profit for the year to Mar 2026 was ₹1.76 Cr, and ₹1.72 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.86.

How much debt does Sandu Pharmaceuticals have?

Sandu Pharmaceuticals reported borrowings of ₹0.41 Cr at Mar 2026, against cash and equivalents of ₹6.85 Cr.

What is the free cash flow of Sandu Pharmaceuticals?

Cash from operations was ₹6.11 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹5.41 Cr.

Loading…